Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 11/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44329 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL789865 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8090809 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL18875934 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL1038060 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL538822 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL7033108 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL8934997 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3095679 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL3675109 | 1.00 | DNM1 (0.52) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217299-A1 | NOVEL LIPIDS CONTAINING DIKETOPIPERAZINE CORE, LIPID NANOPARTICLE CONTAINING THEREOF, AND METHODS OF USING THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-116143707-A | Base ionizable lipid and preparation method and application thereof | 山东大学 | 2023-05-23 | — | — | CN | disclosed |
| EP-3275888-B1 | PROGESTERONE-CATIONIC LIPID HYBRID AS ANTICANCER AGENT AND THE PROCESS OF SYNTHESIS THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-09-25 | — | — | EP | disclosed |
| US-10100079-B2 | Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-10-16 | — | — | US | disclosed |
| US-20180194798-A1 | PROGESTERONE-CATIONIC LIPID HYBRID AS ANTICANCER AGENT AND THE PROCESS OF SYNTHESIS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-12 | — | — | US | disclosed |
| US-20180194798-A1 | PROGESTERONE-CATIONIC LIPID HYBRID AS ANTICANCER AGENT AND THE PROCESS OF SYNTHESIS THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-07-12 | — | — | US | disclosed |
| EP-3275888-A1 | PROGESTERONE-CATIONIC LIPID HYBRID AS ANTICANCER AGENT AND THE PROCESS OF SYNTHESIS THEREOF | Council of Scientific & Industrial Research (IN) | 2018-01-31 | — | — | EP | disclosed |
| EP-2129752-A1 | MIXTURE OF COLD FLOW IMPROVERS AND AMINES | BASF SE (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008113757-A1 | MIXTURE OF COLD FLOW IMPROVERS AND AMINES | BASF SE (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194798-A1 | PROGESTERONE-CATIONIC LIPID HYBRID AS ANTICANCER AGENT AND THE PROCESS OF SYNTHESIS THEREOF | PGR, PGRMC2, PGRMC1 | DNM1 2575/4885TSHR 443/4885MEN1 1788/4885 |
| US-10100079-B2 | Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof | PGR, PGRMC2, PGRMC1 | DNM1 2575/4885TSHR 443/4885MEN1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.